BIONANOPLUS SL

Their core work

BioNanoPlus is a Spanish SME specializing in nanoencapsulation technology — designing and producing nanocapsules that deliver active ingredients in controlled ways for skincare, cosmetics, and antimicrobial applications. They develop adaptive nanoparticle platforms that can target, trigger release, and functionalize active compounds for industrial use. Their work spans from formulation R&D (dermocosmetics, anti-ageing, thermal comfort products) to manufacturing-ready scale-up of nano-enabled products, including safety-by-design approaches for responsible commercialization.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2016), BioNanoPlus focused on the technical foundations of nanoencapsulation — building adaptive platforms for nanocapsules with targeting and triggered-release capabilities, applied to skincare (thermal comfort, anti-ageing, anti-microbial). By the later period (2020-2024), their focus shifted toward responsible commercialization: safety-by-design, production value chains, and market-ready nanoenabled products like antimicrobial coatings and dermocosmetics. This evolution shows a company maturing from lab-scale formulation R&D toward industrial-scale, regulation-aware nano product manufacturing.

BioNanoPlus is moving from R&D-stage nanotechnology toward market-ready, safety-compliant nano-enabled products — making them increasingly relevant for partners seeking production-ready nanoformulation expertise.

How they like to work

BioNanoPlus primarily joins consortia as a specialist partner (2 of 3 projects), contributing nanoformulation know-how to larger teams, though they also led one SME Instrument feasibility study (SAP-Nano). With 27 unique partners across 10 countries from just 3 projects, they operate in medium-to-large consortia and appear comfortable working in diverse, multinational teams. Their single coordinator role was a small-scale feasibility study, suggesting they are best positioned as a high-value technical contributor rather than a consortium manager.

Despite only 3 projects, BioNanoPlus has built a broad network of 27 partners across 10 countries, indicating they participate in well-connected, pan-European consortia focused on nanotechnology and advanced materials.

What sets them apart

BioNanoPlus combines deep nanoencapsulation formulation expertise with practical manufacturing scale-up capability — a rare combination among nano-focused SMEs, which often stay at lab scale. Their progression into safety-by-design means they understand the regulatory pathway for bringing nano-enabled products to market, not just the science behind them. For consortium builders, they offer a production-oriented nano partner who can bridge the gap between academic nanoparticle research and commercial product development.

Highlights from their portfolio

• SKHINCAPS
  Largest project by funding (EUR 498K) and their most technically comprehensive, covering the full nanoencapsulation value chain from formulation to functionalization for skin healthcare.
• ASINA
  Most recent and strategically important — positions them in the growing field of safety-by-design for nanomaterials, with direct commercial applications in antimicrobial coatings and dermocosmetics.
• SAP-Nano
  Their only coordinator role, an SME Instrument Phase 1 exploring a potentially disruptive vaccine manufacturing technology based on self-assembled nanoparticles.